液体生検の世界市場：市場規模・シェア・動向分析 (バイオマーカー別・技術別・試料の種類別、用途別、臨床用途別、最終用途別、製品別・地域別)、セグメント別予測 (2025年～2030年)

液体生検市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の液体生検の市場規模は、2025年から2030年にかけて11.54％のCAGRを記録し、2030年までに228億8,000万米ドルに達すると予測されています。

がんの有病率の増加と老年人口の増加が市場成長を促進する主な要因です。さらに、疾患の早期発見のための技術的に高度な装置の使用は、市場を牽引する主要な要因の1つです。さらに、非侵襲的な治療方法への嗜好の高まりは、予測期間中に有利な機会を提供すると思われます。

近年、がんの罹患者数は著しく増加しており、この動向は当面変わらないと予測されます。ライフスタイルの大幅な変化により、世界の人口がこの障害にさらされ、発がん因子が生じています。例えば、米国がん協会によれば、2022年には新たながん患者数は190万人に達し、60万9,360人が死亡すると予想されています。企業は臨床液体生検領域での事業拡大に注力しています。

例えば、2021年12月、Helio HealthとFulgent Geneticsは、肝臓がん早期発見のための新しい液体生検検査である前者のHelioLiverの発売を発表しました。この液体生検検査は、血清タンパク質マーカーと無細胞DNAメチル化パターンを組み合わせたものです。さらに、新たな研究開発が新規液体生検技術の開発に貢献しています。例えば、2022年7月、セントラルフロリダ大学は、肺がんや乳がんのバイオマーカー同定を用いて早期発見を容易にし、病態のモニタリングを容易にする新規液体生検技術の開発を発表しました。

液体生検に対する各社の関心の高まりと新製品の承認率の上昇が、市場の成長をさらに加速させています。さらにここ数年、液体生検プラットフォームの良好な結果が研究によって示されています。政府や様々な規制機関も、この技術の急速な発展のために複数の画期的な装置を推進することで、この分野に関心を示しています。様々な企業によるこの技術の高い採用率に加え、政府の資金援助やイニシアチブの支援により、市場は今後数年で成長すると予想されます。

液体生検市場：分析概要

• 技術別では、多遺伝子並列解析（NGS）分野が2024年に76.17%の最大収益シェアで市場をリードし、予測期間中に最も速いCAGRで成長すると予測されます。
• バイオマーカーに基づくと、循環腫瘍細胞（CTC）バイオマーカー分野が2024年に35.67％の最大収益シェアで市場をリードしました。エクソソーム/マイクロベシクルセグメントは、予測期間中に13.82%のCAGRで最速成長すると予測されています。
• 用途別では、がん分野が2024年に86.31%の最大収益シェアで市場をリードしました。リプロダクティブヘルス分野は予測期間に12.75%の最速CAGRで成長すると予測されています。
• 最終用途別では、病院・検査室分野が2024年に42.44％の最大収益シェアで市場をリードしました。専門クリニックセグメントは予測期間中12.16%のCAGRで最速成長すると予測されています。
• 臨床応用に基づくと、治療法選択セグメントが2024年に33.69％の最大収益シェアで市場をリードしました。早期スクリーニングセグメントは予測期間に12.38％の最速CAGRで成長すると予測されています。
• 装置セグメントは、2024年に46.74％の最大の収益シェアで市場を独占しました。キットおよび試薬製品セグメントは、予測期間中に大幅なCAGRで成長する見込みです。
• 試料の種類別では、血液サンプルが2024年に71.44％の最大収益シェアで市場をリードし、予測期間中もその優位性を維持すると予測されています。
• 液体生検市場は、北米が2024年に51.15％の最大収益シェアで独占しました。アジア太平洋の液体生検市場は、予測期間中に13.02％の最速CAGRで成長すると予測されます。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 市場の変動要因・傾向・範囲

• 市場区分と範囲
• 市場連関の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
• 市場促進要因の分析
  • がんの罹患率の増加
  • 高齢化人口の増加
  • 技術進歩
  • 非侵襲的治療の人気拡大
• 市場抑制要因の分析
  • ブロックバスター処方薬の特許満了
• ビジネス環境分析
  • SWOT分析；要因別（政治・法律、経済・技術）
  • PESTEL分析

第4章 種類別のビジネス分析

• 液体生検市場：種類別の変動分析
• 血液サンプル
  • 血液サンプル市場（2018～2030年）
• その他
  • その他市場（2018～2030年）

第5章 バイオマーカー別のビジネス分析

• 液体生検市場：バイオマーカー別の変動分析
• 循環腫瘍細胞（CTC）
  • 循環腫瘍細胞（CTC）市場（2018～2030年）
• 循環腫瘍DNA（ctDNA）
  • 循環腫瘍DNA（ctDNA）市場（2018～2030年）
• 細胞外小胞（EV）
  • 細胞外小胞（EV）市場（2018～2030年）
• その他
  • その他市場（2018～2030年）

第6章 技術別のビジネス分析

• 液体生検市場：技術別の変動分析
• マルチ遺伝子並列解析（NGS）
  • マルチ遺伝子並列解析（NGS）市場（2018～2030年）
• 単一遺伝子解析（PCRマイクロアレイ）
  • 単一遺伝子解析（PCRマイクロアレイ）市場（2018～2030年）

第7章 用途別のビジネス分析

• 液体生検市場：用途別の変動分析
• がん
  • がん市場（2018～2030年）
• 生殖医療
  • 生殖医療市場（2018～2030年）
• その他
  • その他市場（2018～2030年）

第8章 最終用途別のビジネス分析

• 液体生検市場：最終用途別の変動分析
• 病院・研究所
  • 病院・検査室市場（2018～2030年）
• 専門クリニック
  • 専門クリニック市場（2018～2030年）
• 学術研究センター
  • 学術研究センター市場（2018～2030年）
• その他
  • その他の液体生検市場（2018～2030年）

第9章 臨床用途別のビジネス分析

• 液体生検市場：臨床用途別の変動分析
• 治療法選択
  • 治療法選択市場（2018～2030年）
• 治療モニタリング
  • 治療モニタリング市場（2018～2030年）
• 早期がん検診
  • 早期がんスクリーニング市場（2018～2030年）
• 再発モニタリング
  • 再発モニタリング市場（2018～2030年）
• その他
  • その他の液体生検市場（2018～2030年）

第10章 製品別のビジネス分析

• 液体生検市場：製品別の変動分析
• 装置
  • 装置市場（2018～2030年）
• 消耗品キット・試薬
  • 消耗品キット・試薬市場（2018～2030年）
• ソフトウェア・サービス
  • ソフトウェア・サービス市場（2018～2030年）

第11章 地域別のビジネス分析

• 液体生検の市場シェア、地域別（2024年・2030年）
• 北米
  • 北米の液体生検市場（2018～2030年）
  • 米国
  • カナダ
• 欧州
  • 欧州の液体生検市場（2018～2030年）
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • アジア太平洋の液体生検市場（2018～2030年）
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • ラテンアメリカの液体生検市場（2018～2030年）
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 中東・アフリカの液体生検市場（2018～2030年）
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第12章 競合情勢

• 参入企業の概要
• 財務実績
• 参入企業
  • 塩生リーダー
  • 液体生検の市場シェア分析（2024年）
  • 企業プロファイル
  • 戦略マッピング

List of Tables

• Table 1 Global Liquid Biopsy Market, By Region, 2018 - 2030 (USD Million)
• Table 2 Global Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 3 Global Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 4 Global Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 5 Global Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 6 Global Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 7 Global Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 8 Global Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 9 North America Liquid Biopsy Market, By Country, 2018 - 2030 (USD Million)
• Table 10 North America Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 11 North America Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 12 North America Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 13 North America Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 14 North America Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 15 North America Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 16 North America Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 17 U.S. Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 18 U.S. Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 19 U.S. Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 20 U.S. Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 21 U.S. Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 22 U.S. Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 23 U.S. Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 24 Canada Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 25 Canada Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 26 Canada Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 27 Canada Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 28 Canada Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 29 Canada Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 30 Canada Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 31 Europe Liquid Biopsy Market, By Country, 2018 - 2030 (USD Million)
• Table 32 Europe Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 33 Europe Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 34 Europe Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 35 Europe Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 36 Europe Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 37 Europe Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 38 Europe Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 39 UK Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 40 UK Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 41 UK Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 42 UK Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 43 UK Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 44 UK Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 45 UK Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 46 Germany Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 47 Germany Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 48 Germany Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 49 Germany Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 50 Germany Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 51 Germany Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 52 Germany Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 53 France Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 54 France Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 55 France Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 56 France Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 57 France Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 58 France Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 59 France Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 60 Italy Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 61 Italy Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 62 Italy Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 63 Italy Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 64 Italy Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 65 Italy Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 66 Italy Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 67 Spain Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 68 Spain Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 69 Spain Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 70 Spain Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 71 Spain Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 72 Spain Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 73 Spain Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 74 Denmark Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 75 Denmark Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 76 Denmark Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 77 Denmark Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 78 Denmark Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 79 Denmark Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 80 Denmark Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 81 Sweden Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 82 Sweden Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 83 Sweden Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 84 Sweden Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 85 Sweden Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 86 Sweden Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 87 Sweden Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 88 Norway Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 89 Norway Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 90 Norway Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 91 Norway Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 92 Norway Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 93 Norway Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 94 Norway Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 95 Asia Pacific Liquid Biopsy Market, By Country, 2018 - 2030 (USD Million)
• Table 96 Asia Pacific Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 97 Asia Pacific Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 98 Asia Pacific Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 99 Asia Pacific Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 100 Asia Pacific Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 101 Asia Pacific Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 102 Asia Pacific Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 103 Japan Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 104 Japan Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 105 Japan Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 106 Japan Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 107 Japan Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 108 Japan Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 109 Japan Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 110 China Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 111 China Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 112 China Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 113 China Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 114 China Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 115 China Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 116 China Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 117 India Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 118 India Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 119 India Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 120 India Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 121 India Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 122 India Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 123 India Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 124 Australia Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 125 Australia Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 126 Australia Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 127 Australia Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 128 Australia Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 129 Australia Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 130 Australia Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 131 South Korea Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 132 South Korea Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 133 South Korea Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 134 South Korea Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 135 South Korea Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 136 South Korea Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 137 South Korea Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 138 Thailand Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 139 Thailand Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 140 Thailand Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 141 Thailand Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 142 Thailand Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 143 Thailand Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 144 Thailand Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 145 Latin America Liquid Biopsy Market, By Country, 2018 - 2030 (USD Million)
• Table 146 Latin America Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 147 Latin America Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 148 Latin America Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 149 Latin America Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 150 Latin America Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 151 Latin America Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 152 Latin America Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 153 Brazil Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 154 Brazil Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 155 Brazil Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 156 Brazil Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 157 Brazil Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 158 Brazil Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 159 Brazil Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 160 Mexico Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 161 Mexico Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 162 Mexico Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 163 Mexico Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 164 Mexico Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 165 Mexico Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 166 Mexico Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 167 Argentina Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 168 Argentina Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 169 Argentina Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 170 Argentina Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 171 Argentina Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 172 Argentina Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 173 Argentina Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 174 Middle East & Africa Liquid Biopsy Market, By Country, 2018 - 2030 (USD Million)
• Table 175 Middle East & Africa Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 176 Middle East & Africa Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 177 Middle East & Africa Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 178 Middle East & Africa Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 179 Middle East & Africa Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 180 Middle East & Africa Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 181 Middle East & Africa Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 182 South Africa Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 183 South Africa Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 184 South Africa Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 185 South Africa Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 186 South Africa Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 187 South Africa Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 188 South Africa Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 189 Saudi Arabia Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 190 Saudi Arabia Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 191 Saudi Arabia Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 192 Saudi Arabia Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 193 Saudi Arabia Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 194 Saudi Arabia Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 195 Saudi Arabia Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 196 UAE Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 197 UAE Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 198 UAE Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 199 UAE Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 200 UAE Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 201 UAE Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 202 UAE Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)
• Table 203 Kuwait Liquid Biopsy Market, By Sample Type, 2018 - 2030 (USD Million)
• Table 204 Kuwait Liquid Biopsy Market, By Biomarker, 2018 - 2030 (USD Million)
• Table 205 Kuwait Liquid Biopsy Market, By Technology, 2018 - 2030 (USD Million)
• Table 206 Kuwait Liquid Biopsy Market, By Application, 2018 - 2030 (USD Million)
• Table 207 Kuwait Liquid Biopsy Market, By End Use, 2018 - 2030 (USD Million)
• Table 208 Kuwait Liquid Biopsy Market, By Clinical Application, 2018 - 2030 (USD Million)
• Table 209 Kuwait Liquid Biopsy Market, By Product, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value chain-based sizing & forecasting
• Fig. 6 Market formulation & validation
• Fig. 7 Liquid biopsy market segmentation
• Fig. 8 Market driver relevance analysis (Current & future impact)
• Fig. 9 Market restraint relevance analysis (Current & future impact)
• Fig. 10 Market challenge relevance analysis (Current & future impact)
• Fig. 11 Penetration & growth prospect mapping
• Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
• Fig. 13 Porter's five forces analysis
• Fig. 14 Market penetration vs growth prospect mapping
• Fig. 15 Liquid biopsy market: Sample Type movement analysis
• Fig. 16 Blood sample liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 17 Other liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 18 Liquid biopsy market: Biomarker movement analysis
• Fig. 19 Circulating Tumor Cells (CTCs) liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 20 Circulating Tumor DNA (ctDNA) liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 21 Extracellular Vehicles (EVs) liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 22 Other liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 23 Liquid biopsy market: Technology movement analysis
• Fig. 24 Multi-gene-parallel analysis (NGS) liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 25 Single gene analysis (PCR Microarrays) liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 26 Liquid biopsy market: Application movement analysis
• Fig. 27 Cancer liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 28 Lung cancer liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 29 Prostate cancer liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 30 Breast cancer liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 31 Colorectal cancer liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 32 Leukemia liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 33 Gastrointestinal cancer liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 34 Other liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 35 Reproductive Health liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 36 Other liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 37 Liquid biopsy market: End Use movement analysis
• Fig. 38 Hospitals and Laboratories liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 39 Specialty clinics liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 40 Academic and research centers liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 41 Other liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 42 Liquid biopsy market: Clinical application movement analysis
• Fig. 43 Therapy selection liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 44 Treatment monitoring liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 45 Early cancer screening liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 46 Recurrence monitoring liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 47 Other liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 48 Liquid biopsy market: Product movement analysis
• Fig. 49 Instruments liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 50 Consumables kits and reagents liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 51 Software and Services liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 52 Regional marketplace: Key takeaways
• Fig. 53 Regional outlook, 2018 & 2030
• Fig. 54 North America liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 55 U.S. liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 56 Canada liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 57 Europe liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 58 UK liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 59 Germany liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 60 Italy liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 61 Spain liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 62 France liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 63 Denmark liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 64 Sweden liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 65 Norway liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 66 Asia Pacific liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 67 Japan liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 68 China liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 69 India liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 70 Australia liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 71 South Korea liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 72 Thailand liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 73 Latin America liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 74 Brazil liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 75 Mexico liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 76 Argentina liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 77 MEA liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 78 South Africa liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 79 Saudi Arabia liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 80 UAE liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 81 Kuwait liquid biopsy market, 2018 - 2030 (USD Million)

Liquid Biopsy Market Growth & Trends:

The global liquid biopsy market size is expected to reach USD 22.88 billion by 2030, registering a CAGR of 11.54% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of cancer and the growing geriatric population are major drivers expected to fuel market growth. Furthermore, the use of technologically advanced devices for early detection of diseases is one of the key factors driving the market. In addition, the increasing preference for noninvasive treatment procedures will offer lucrative opportunities in the forecast period.

In recent years, cases of cancer have been rising tremendously and the trend is projected to remain the same in the foreseeable future. A significant shift in lifestyle has exposed the global population to this disorder and has resulted in oncogenic factors. For instance, as per the American Cancer Society, in 2022, the number of new cancer cases is expected to reach 1.9 million, leading to 609,360 deaths. Companies are focusing on expanding their business operations in the clinical liquid biopsy space.

For instance, in December 2021, Helio Health and Fulgent Genetics announced the launch of the former's HelioLiver, a new liquid biopsy test for early liver cancer detection. This liquid biopsy test combines serum protein markers and cell-free DNA methylation patterns. Additionally, new research studies are aiding the development of novel liquid biopsy techniques. For instance, in July 2022, the University of Central Florida announced the development of a novel liquid biopsy technique that facilitates early detection using biomarker identification for lung and breast cancer, making the monitoring of conditions easier.

The enhanced interest of players in liquid biopsy and the increasing rate of approval of new products are further accelerating market growth. Moreover, in the past several years, studies have shown a positive outcome of liquid biopsy platforms. Governments and various regulatory bodies have also shown interest in the area by promoting multiple breakthrough devices for the rapid development of this technology. With the high adoption of the technology by various companies, along with the support of government funding and initiatives, the market is expected to grow in the coming years.

Liquid Biopsy Market Report Highlights:

• Based on technology, the multi-gene-parallel analysis (NGS) segment led the market with the largest revenue share of 76.17% in 2024 and is anticipated to grow at the fastest CAGR over the forecast period.
• Based on biomarker, the circulating tumor cells (CTC) biomarker segment led the market with the largest revenue share of 35.67% in 2024. The exosomes/microvesicles segment is anticipated to grow at the fastest CAGR of 13.82% over the forecast period.
• Based on application, the cancer segment led the market with the largest revenue share of 86.31% in 2024.The reproductive health segment is anticipated to grow at the fastest CAGR of 12.75% over the forecast period.
• Based on end use, the hospitals and laboratories segment led the market with the largest revenue share of 42.44% in 2024. The specialty clinics segment is anticipated to grow at the fastest CAGR of 12.16% over the forecast period.
• Based on clinical application, the therapy selection segment led the market with the largest revenue share of 33.69% in 2024.The early screening segment is expected to grow at the fastest CAGR of 12.38% over the forecast period.
• The instruments product segment dominated the market with the largest revenue share of 46.74% in 2024.The kits and reagents product segment is expected to grow at a significant CAGR during the forecast period.
• Based on sample type, the blood sample segment led the market with the largest revenue share of 71.44% in 2024 and is projected to maintain its dominance over the forecast period.
• North America dominated the liquid biopsy market with the largest revenue share of 51.15% in 2024.The liquid biopsy market in Asia Pacific is expected to grow at the fastest CAGR of 13.02% over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation
  • 1.1.1. Market Definitions
• 1.2. Objectives
  • 1.2.1. Objective - 1
  • 1.2.2. Objective - 2
  • 1.2.3. Objective - 3
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers
  • 3.4.1. Increasing prevalence of cancer
  • 3.4.2. Growing geriatric population
  • 3.4.3. Technological advancements
  • 3.4.4. Increasing preference for noninvasive treatment
• 3.5. Market Restraint Analysis
  • 3.5.1. Patent expiry of blockbuster drugs prescribed
• 3.6. Business Environment Analysis
  • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
  • 3.6.2. Porter's Five Forces Analysis

Chapter 4. Type Business Analysis

• 4.1. Liquid Biopsy Market: Type Movement Analysis
• 4.2. Blood Sample
  • 4.2.1. Blood Sample Market, 2018 - 2030 (USD Million)
• 4.3. Others
  • 4.3.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Biomarker Business Analysis

• 5.1. Liquid Biopsy Market: Biomarker Movement Analysis
• 5.2. Circulating Tumor Cells (CTCs)
  • 5.2.1. Circulating Tumor Cells (CTCs) Market, 2018 - 2030 (USD Million)
• 5.3. Circulating Tumor DNA (ctDNA)
  • 5.3.1. Circulating Tumor DNA (ctDNA) Market, 2018 - 2030 (USD Million)
• 5.4. Extracellular Vehicles (EVs)
  • 5.4.1. Extracellular Vehicles (EVs) Market, 2018 - 2030 (USD Million)
• 5.5. Others
  • 5.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Technology Business Analysis

• 6.1. Liquid Biopsy Market: Technology Movement Analysis
• 6.2. Multi-gene-parallel Analysis (NGS)
  • 6.2.1. Multi-gene-parallel Analysis (NGS) Market, 2018 - 2030 (USD Million)
• 6.3. Single Gene Analysis (PCR Microarrays)
  • 6.3.1. Single Gene Analysis (PCR Microarrays) Market, 2018 - 2030 (USD Million)

Chapter 7. Application Business Analysis

• 7.1. Liquid Biopsy Market: Application Movement Analysis
• 7.2. Cancer
  • 7.2.1. Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.1.1. Lung Cancer
      • 7.2.1.1.1. Lung Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.1.2. Prostate Cancer
      • 7.2.1.2.1. Prostate Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.1.3. Breast Cancer
      • 7.2.1.3.1. Breast Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.1.4. Colorectal Cancer
      • 7.2.1.4.1. Colorectal Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.1.5. Leukemia
      • 7.2.1.5.1. Leukemia Market, 2018 - 2030 (USD Million)
    • 7.2.1.6. Gastrointestinal Cancer
      • 7.2.1.6.1. Gastrointestinal Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.1.7. Others
      • 7.2.1.7.1. Others Market, 2018 - 2030 (USD Million)
• 7.3. Reproductive Health
  • 7.3.1. Reproductive Health Market, 2018 - 2030 (USD Million)
• 7.4. Others
  • 7.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. End-Use Business Analysis

• 8.1. Liquid Biopsy Market: End-Use Movement Analysis
• 8.2. Hospitals and Laboratories
  • 8.2.1. Hospitals and Laboratories Market, 2018 - 2030 (USD Million)
• 8.3. Specialty Clinics
  • 8.3.1. Specialty Clinics Market, 2018 - 2030 (USD Million)
• 8.4. Academic and Research Centers
  • 8.4.1. Academic and Research Centers Market, 2018 - 2030 (USD Million)
• 8.5. Others
  • 8.5.1. Others Liquid Biopsy Market, 2018 - 2030 (USD Million)

Chapter 9. Clinical Application Business Analysis

• 9.1. Liquid Biopsy Market: Clinical Application Movement Analysis
• 9.2. Therapy Selection
  • 9.2.1. Therapy Selection Market, 2018 - 2030 (USD Million)
• 9.3. Treatment Monitoring
  • 9.3.1. Treatment Monitoring Market, 2018 - 2030 (USD Million)
• 9.4. Early Cancer Screening
  • 9.4.1. Early Cancer Screening Market, 2018 - 2030 (USD Million)
• 9.5. Recurrence Monitoring
  • 9.5.1. Recurrence Monitoring Market, 2018 - 2030 (USD Million)
• 9.6. Others
  • 9.6.1. Others Liquid Biopsy Market, 2018 - 2030 (USD Million)

Chapter 10. Product Business Analysis

• 10.1. Liquid Biopsy Market: Product Movement Analysis
• 10.2. Instruments
  • 10.2.1. Instruments Market, 2018 - 2030 (USD Million)
• 10.3. Consumables Kits, and Reagents
  • 10.3.1. Consumables Kits and Reagents Market, 2018 - 2030 (USD Million)
• 10.4. Software and Services
  • 10.4.1. Software and Services Market, 2018 - 2030 (USD Million)

Chapter 11. Regional Business Analysis

• 11.1. Liquid Biopsy Market Share, By Region, 2024 & 2030
• 11.2. North America
  • 11.2.1. North America Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.2.2. U.S.
    • 11.2.2.1. Key Country Dynamics
    • 11.2.2.2. Target Disease Prevalence
    • 11.2.2.3. Competitive Scenario
    • 11.2.2.4. Regulatory Framework
    • 11.2.2.5. Reimbursement Scenario
    • 11.2.2.6. U.S. Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.2.3. Canada
    • 11.2.3.1. Key Country Dynamics
    • 11.2.3.2. Target Disease Prevalence
    • 11.2.3.3. Competitive Scenario
    • 11.2.3.4. Regulatory Framework
    • 11.2.3.5. Reimbursement Scenario
    • 11.2.3.6. Canada Liquid biopsy market, 2018 - 2030 (USD Million)
• 11.3. Europe
  • 11.3.1. Europe Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.3.2. Germany
    • 11.3.2.1. Key Country Dynamics
    • 11.3.2.2. Target Disease Prevalence
    • 11.3.2.3. Competitive Scenario
    • 11.3.2.4. Regulatory Framework
    • 11.3.2.5. Reimbursement Scenario
    • 11.3.2.6. Germany Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.3.3. UK
    • 11.3.3.1. Key Country Dynamics
    • 11.3.3.2. Target Disease Prevalence
    • 11.3.3.3. Competitive Scenario
    • 11.3.3.4. Regulatory Framework
    • 11.3.3.5. Reimbursement Scenario
    • 11.3.3.6. UK Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.3.4. France
    • 11.3.4.1. Key Country Dynamics
    • 11.3.4.2. Target Disease Prevalence
    • 11.3.4.3. Competitive Scenario
    • 11.3.4.4. Regulatory Framework
    • 11.3.4.5. Reimbursement Scenario
    • 11.3.4.6. France Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.3.5. Italy
    • 11.3.5.1. Key Country Dynamics
    • 11.3.5.2. Target Disease Prevalence
    • 11.3.5.3. Competitive Scenario
    • 11.3.5.4. Regulatory Framework
    • 11.3.5.5. Reimbursement Scenario
    • 11.3.5.6. Italy Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.3.6. Spain
    • 11.3.6.1. Key Country Dynamics
    • 11.3.6.2. Target Disease Prevalence
    • 11.3.6.3. Competitive Scenario
    • 11.3.6.4. Regulatory Framework
    • 11.3.6.5. Reimbursement Scenario
    • 11.3.6.6. Spain Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.3.7. Denmark
    • 11.3.7.1. Key Country Dynamics
    • 11.3.7.2. Target Disease Prevalence
    • 11.3.7.3. Competitive Scenario
    • 11.3.7.4. Regulatory Framework
    • 11.3.7.5. Reimbursement Scenario
    • 11.3.7.6. Denmark Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.3.8. Sweden
    • 11.3.8.1. Key Country Dynamics
    • 11.3.8.2. Target Disease Prevalence
    • 11.3.8.3. Competitive Scenario
    • 11.3.8.4. Regulatory Framework
    • 11.3.8.5. Reimbursement Scenario
    • 11.3.8.6. Sweden Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.3.9. Norway
    • 11.3.9.1. Key Country Dynamics
    • 11.3.9.2. Target Disease Prevalence
    • 11.3.9.3. Competitive Scenario
    • 11.3.9.4. Regulatory Framework
    • 11.3.9.5. Reimbursement Scenario
    • 11.3.9.6. Norway Liquid biopsy market, 2018 - 2030 (USD Million)
• 11.4. Asia Pacific
  • 11.4.1. Asia Pacific Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.4.2. Japan
    • 11.4.2.1. Key Country Dynamics
    • 11.4.2.2. Target Disease Prevalence
    • 11.4.2.3. Competitive Scenario
    • 11.4.2.4. Regulatory Framework
    • 11.4.2.5. Reimbursement Scenario
    • 11.4.2.6. Japan Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.4.3. China
    • 11.4.3.1. Key Country Dynamics
    • 11.4.3.2. Target Disease Prevalence
    • 11.4.3.3. Competitive Scenario
    • 11.4.3.4. Regulatory Framework
    • 11.4.3.5. Reimbursement Scenario
    • 11.4.3.6. China Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.4.4. India
    • 11.4.4.1. Key Country Dynamics
    • 11.4.4.2. Target Disease Prevalence
    • 11.4.4.3. Competitive Scenario
    • 11.4.4.4. Regulatory Framework
    • 11.4.4.5. Reimbursement Scenario
    • 11.4.4.6. India Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.4.5. South Korea
    • 11.4.5.1. Key Country Dynamics
    • 11.4.5.2. Target Disease Prevalence
    • 11.4.5.3. Competitive Scenario
    • 11.4.5.4. Regulatory Framework
    • 11.4.5.5. Reimbursement Scenario
    • 11.4.5.6. South Korea Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.4.6. Australia
    • 11.4.6.1. Key Country Dynamics
    • 11.4.6.2. Target Disease Prevalence
    • 11.4.6.3. Competitive Scenario
    • 11.4.6.4. Regulatory Framework
    • 11.4.6.5. Reimbursement Scenario
    • 11.4.6.6. Australia Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.4.7. Thailand
    • 11.4.7.1. Key Country Dynamics
    • 11.4.7.2. Target Disease Prevalence
    • 11.4.7.3. Competitive Scenario
    • 11.4.7.4. Regulatory Framework
    • 11.4.7.5. Reimbursement Scenario
    • 11.4.7.6. Thailand Liquid biopsy market, 2018 - 2030 (USD Million)
• 11.5. Latin America
  • 11.5.1. Latin America Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.5.2. Brazil
    • 11.5.2.1. Key Country Dynamics
    • 11.5.2.2. Target Disease Prevalence
    • 11.5.2.3. Competitive Scenario
    • 11.5.2.4. Regulatory Framework
    • 11.5.2.5. Reimbursement Scenario
    • 11.5.2.6. Brazil Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.5.3. Mexico
    • 11.5.3.1. Key Country Dynamics
    • 11.5.3.2. Target Disease Prevalence
    • 11.5.3.3. Competitive Scenario
    • 11.5.3.4. Regulatory Framework
    • 11.5.3.5. Reimbursement Scenario
    • 11.5.3.6. Mexico Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.5.4. Argentina
    • 11.5.4.1. Key Country Dynamics
    • 11.5.4.2. Target Disease Prevalence
    • 11.5.4.3. Competitive Scenario
    • 11.5.4.4. Regulatory Framework
    • 11.5.4.5. Reimbursement Scenario
    • 11.5.4.6. Argentina Liquid biopsy market, 2018 - 2030 (USD Million)
• 11.6. MEA
  • 11.6.1. MEA Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.6.2. South Africa
    • 11.6.2.1. Key Country Dynamics
    • 11.6.2.2. Target Disease Prevalence
    • 11.6.2.3. Competitive Scenario
    • 11.6.2.4. Regulatory Framework
    • 11.6.2.5. Reimbursement Scenario
    • 11.6.2.6. South Africa Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.6.3. Saudi Arabia
    • 11.6.3.1. Key Country Dynamics
    • 11.6.3.2. Target Disease Prevalence
    • 11.6.3.3. Competitive Scenario
    • 11.6.3.4. Regulatory Framework
    • 11.6.3.5. Reimbursement Scenario
    • 11.6.3.6. Saudi Arabia Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.6.4. UAE
    • 11.6.4.1. Key Country Dynamics
    • 11.6.4.2. Target Disease Prevalence
    • 11.6.4.3. Competitive Scenario
    • 11.6.4.4. Regulatory Framework
    • 11.6.4.5. Reimbursement Scenario
    • 11.6.4.6. UAE Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.6.5. Kuwait
    • 11.6.5.1. Key Country Dynamics
    • 11.6.5.2. Target Disease Prevalence
    • 11.6.5.3. Competitive Scenario
    • 11.6.5.4. Regulatory Framework
    • 11.6.5.5. Reimbursement Scenario
    • 11.6.5.6. Kuwait Liquid biopsy market, 2018 - 2030 (USD Million)

Chapter 12. Competitive Landscape

• 12.1. Participant's overview
• 12.2. Financial performance
• 12.3. Participant categorization
  • 12.3.1. Market Leaders
  • 12.3.2. Liquid Biopsy Market Share Analysis, 2024
  • 12.3.3. Company Profiles
    • 12.3.3.1. ANGLE plc
      • 12.3.3.1.1. Company Overview
      • 12.3.3.1.2. Financial Performance
      • 12.3.3.1.3. Product Benchmarking
      • 12.3.3.1.4. Strategic Initiatives
    • 12.3.3.2. Oncimmune Holdings PLC
      • 12.3.3.2.1. Company Overview
      • 12.3.3.2.2. Financial Performance
      • 12.3.3.2.3. Product Benchmarking
      • 12.3.3.2.4. Strategic Initiatives
    • 12.3.3.3. Guardant Health
      • 12.3.3.3.1. Company Overview
      • 12.3.3.3.2. Financial Performance
      • 12.3.3.3.3. Product Benchmarking
      • 12.3.3.3.4. Strategic Initiatives
    • 12.3.3.4. Myriad Genetics, Inc.
      • 12.3.3.4.1. Company Overview
      • 12.3.3.4.2. Financial Performance
      • 12.3.3.4.3. Product Benchmarking
      • 12.3.3.4.4. Strategic Initiatives
    • 12.3.3.5. Biocept, Inc.
      • 12.3.3.5.1. Company Overview
      • 12.3.3.5.2. Financial Performance
      • 12.3.3.5.3. Product Benchmarking
      • 12.3.3.5.4. Strategic Initiatives
    • 12.3.3.6. Lucence Health Inc.
      • 12.3.3.6.1. Company Overview
      • 12.3.3.6.2. Financial Performance
      • 12.3.3.6.3. Product Benchmarking
      • 12.3.3.6.4. Strategic Initiatives
    • 12.3.3.7. Freenome Holdings, Inc.
      • 12.3.3.7.1. Company Overview
      • 12.3.3.7.2. Financial Performance
      • 12.3.3.7.3. Product Benchmarking
      • 12.3.3.7.4. Strategic Initiatives
    • 12.3.3.8. F. Hoffmann-La Roche Ltd.
      • 12.3.3.8.1. Company Overview
      • 12.3.3.8.2. Financial Performance
      • 12.3.3.8.3. Product Benchmarking
      • 12.3.3.8.4. Strategic Initiatives
    • 12.3.3.9. QIAGEN
      • 12.3.3.9.1. Company Overview
      • 12.3.3.9.2. Financial Performance
      • 12.3.3.9.3. Product Benchmarking
      • 12.3.3.9.4. Strategic Initiatives
    • 12.3.3.10. Illumina, Inc.
      • 12.3.3.10.1. Company Overview
      • 12.3.3.10.2. Financial Performance
      • 12.3.3.10.3. Product Benchmarking
      • 12.3.3.10.4. Strategic Initiatives
    • 12.3.3.11. Thermo Fisher Scientific, Inc.
      • 12.3.3.11.1. Company Overview
      • 12.3.3.11.2. Financial Performance
      • 12.3.3.11.3. Product Benchmarking
      • 12.3.3.11.4. Strategic Initiatives
    • 12.3.3.12. Epigenomics AG
      • 12.3.3.12.1. Company Overview
      • 12.3.3.12.2. Financial Performance
      • 12.3.3.12.3. Product Benchmarking
      • 12.3.3.12.4. Strategic Initiatives
  • 12.3.4. Strategy Mapping
    • 12.3.4.1. Expansion
    • 12.3.4.2. Acquisition
    • 12.3.4.3. Collaborations
    • 12.3.4.4. Disease Type/Drug Class Launch
    • 12.3.4.5. Partnerships
    • 12.3.4.6. Others